Vaxart has dosed the first participant in its Phase II clinical trial of an oral tablet vaccine for the treatment of Covid-19.

For the trial’s first part, 96 participants will be enrolled at four centres in the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The US part will be an open-label, randomised dose and age escalation lead-in segment in untreated and previously inoculated participants.

Participants aged 18-75 years will be categorised into eight arms based on their age, inoculation history, and dosage size to receive either the oral tablet vaccine or placebo on day one and day 29.

Safety, immunogenicity and efficacy are the goals of the trial.

The company anticipates complete results from the US trial in the first quarter of next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A global placebo-controlled efficacy trial will be initiated on concluding the US trial.

Vaxart founder and chief scientific officer Dr Sean Tucker said: “A vaccine that can inhibit infection in the mucosal surfaces provides potentially better protection against airborne viruses because the mucosa is the body’s first line of defence against these pathogens.

“The mucosa is where the virus invades, and if we can stop it there, we can keep people healthier and fight off this virus and its variants.”

The company develops vaccines that can be administered as tablets, which can be stored and transported without requiring refrigeration while eradiating needle-stick injury risks.

Vaxart’s development programmes currently comprise tablet vaccines to offer protection against coronavirus, norovirus, seasonal influenza, respiratory syncytial virus and therapeutic vaccine for human papillomavirus.

Earlier this month, Vaxart initiated participant recruitment in the Phase II trial of the S-only oral tablet vaccine candidate to treat Covid-19.